Breaking news on life science and diagnostics business, policy, and funding
The partners will identify patients with gastrointestinal or endometrial cancers who may benefit from immune checkpoint inhibitor therapy using Biotype's technology.
The company plans to add 150 to 200 new employees and is quadrupling its space in Pleasanton, California, including a manufacturing site for its microfluidic chips.
Shivom and Lifebit will offer an artificial intelligence-based platform for identifying the right patients for enrollment in clinical trials.
The company aims to position its platform as a validation tool for CRISPR-based therapeutics, while continuing to grow in the oncology space.
The startup plans to use the funds to scale its single-cell DNA analysis technology for blood-based cancer research and expand into CRISPR applications.
The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.